Table 1.
Patient Demographics and Baseline Characteristics
| Recurrent Glioma Cohort | |||
|---|---|---|---|
| IDH-Mutant 1p/19q Co-Deleted Oligodendroglioma | IDH-Mutant Astrocytoma | Total | |
| N | 34 | 48 | 82 |
| Sex | |||
| Male | 16 (47.1) | 28 (58.3) | 44 (53.7) |
| Female | 18 (52.9) | 20 (41.7) | 38 (46.3) |
| Age at diagnosis, median (range) | 38 (17-66) | 31 (22-49) | 34 (17-66) |
| Prior treatment | |||
| TMZ | 27 (79.4) | 36 (76.6) | 63 (76.8) |
| RT | 10 (29.4) | 12 (25.5) | 22 (26.8) |
| Transformed | 28 (82.4) | 38 (79.2) | 66 (80.5) |
| Grade III | 28 (82.4) | 20 (41.7) | 48 (58.5) |
| Grade IV | - | 18 (37.5) | 18 (22.0) |
| Hypermutation | 15 (44.1) | 16 (33.3) | 31 (37.8) |
| Transformed Tumors | |||
| IDH-Mutant Co-Deleted Oligodendroglioma | IDH-Mutant Astrocytoma | Total | |
| N | 28 | 38 | 66 |
| Sex | |||
| Male (%) | 13 (46.4) | 22 (57.9) | 35 (53.0) |
| Female (%) | 15 (53.6) | 16 (42.1) | 31 (47.0) |
| Age at diagnosis, median (range) | 38 (17-66) | 32 (22-49) | 35 (17-66) |
| Age at transformation, median (range) | 46 (22-71) | 37 (23-56) | 43 (22-71) |
| Years to transformation, median (range) | 6.9 (2.6-16.4) | 5.6 (1.3-16.1) | 5.9 (1.3-16.4) |
| TMZ months, median (range) | 15.4 (0-27) | 10.4 (0-30) | 12 (0-30) |
| KPS at transformation, median (range) | 90 (10-90) | 90 (70-100) | 90 (10-100) |
| CDKN2A homozygous deletion (%) | 2 (7.1) | 2 (5.3) | 4 (6.1) |
| Extent of resection (%) | |||
| Gross total resection | 2 (7.1) | 5 (13.2) | 7 (10.6) |
| Subtotal resection | 23 (82.1) | 31 (81.6) | 54 (81.8) |
| Biopsy | 0 (0.0) | 1(2.6) | 1 (1.5) |
| Prior treatment (%) | |||
| TMZ | 23 (82.1) | 30 (79.0) | 53 (80.3) |
| RT | 10 (35.7) | 11 (28.9) | 21 (31.8) |
| Transformation (%) | |||
| Grade III | 28 (100) | 20 (52.6) | 48 (72.7) |
| Grade IV | - | 18 (47.4) | 18 (27.3) |
| Hypermutation (%) | 14 (50.0) | 16 (42.1) | 30 (45.4) |
Abbreviations: IDH, isocitrate dehydrogenase; KPS, Karnofsky performance status; RT, radiation therapy; TMZ, temozolomide.